8-KFiled Aug 13, 8:00 PM ET

Citius Oncology Reports Q3 Fiscal 2026 Results

$CTOR · CITIUS ONCOLOGY, INC.

Research Summary

AI-generated summary of this SEC filing

Updated

Citius Oncology Reports Q3 Fiscal 2026 Results

What Happened Citius Oncology, Inc. announced its results of operations for the third quarter of fiscal 2026 via a press release dated August 14, 2026. The company filed a Form 8‑K (Item 2.02) furnishing that press release, which is included as Exhibit 99.1 to the filing.

Key Details

  • Filed Form 8-K on August 14, 2026 reporting results of operations and financial condition (Item 2.02).
  • Press release announcing Q3 fiscal 2026 results is furnished as Exhibit 99.1 to the 8‑K.
  • The filing also includes the Inline XBRL cover page (Exhibit 104).
  • The 8‑K itself furnishes the press release rather than embedding the full financial statements in the Form 8‑K.

Why It Matters Quarterly results are a primary source of updated information on a company’s earnings, revenue trends and cash position; they can affect investor expectations and share price. Investors should read the attached press release (Exhibit 99.1) for the specific revenue, profit/loss, cash balance and any management commentary or guidance, and consult Citius Oncology’s subsequent SEC filings (e.g., Form 10‑Q) for reconciled financial statements and additional detail.